## Core Concept
The prognosis in Acute Myeloid Leukemia (AML) is determined by various factors including cytogenetic and molecular abnormalities, age of the patient, and the presence of specific mutations. Certain genetic mutations and chromosomal abnormalities are associated with a worse prognosis.

## Why the Correct Answer is Right
The correct answer, , is associated with a bad prognosis in AML. This is because specific genetic abnormalities, such as those involving the MLL gene (also known as KMT2A), complex karyotype, or certain molecular mutations like FLT3-ITD, NPM1 mutation without FLT3-ITD, and others, can significantly impact the outcome. The MLL gene rearrangement is particularly noted for its association with a poorer prognosis, especially in cases of therapy-related AML or AML arising from a background of myelodysplastic syndromes.

## Why Each Wrong Option is Incorrect
* **Option A:** Certain genetic mutations like t(8;21) or inv(16) are actually associated with a relatively good prognosis in AML, especially when treated appropriately.
* **Option B:** Some specific genetic markers or cytogenetic abnormalities might not necessarily indicate a bad prognosis; their impact can vary based on the presence of other mutations or the specific subtype of AML.
* **Option D:** Without specifying what is, it's hard to directly refute it. However, generally, certain mutations or chromosomal translocations are associated with an intermediate or even favorable prognosis in AML.

## Clinical Pearl / High-Yield Fact
A key clinical pearl is that the presence of FLT3-ITD mutation, particularly in the absence of a NPM1 mutation, is associated with a worse prognosis in AML patients. Conversely, NPM1 mutation without FLT3-ITD is considered to have an intermediate to favorable prognosis. Understanding these genetic underpinnings is crucial for risk stratification and guiding treatment decisions.

## Correct Answer Line
**Correct Answer: C.**